机构：[1]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Chest Oncology Institute, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[3]Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, China.
To investigate the predictive value of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
We conducted a systemic search of PubMed, EMBASE, and the Cochrane Library from 1 January 2000 to 30 August 2020, to identify related studies. We combined the hazard ratio (HR) and 95% confidence interval (CI) to assess the correlation of PD-L1 expression with progression-free survival (PFS) and overall survival (OS). We assessed the quality of the included studies by the Newcastle-Ottawa Scale (NOS). We performed subgroup analyses based on immunohistochemistry (IHC) scoring system, IHC antibodies, sample size, countries, and survival analysis mode. Sensitivity analysis and evaluation of publication bias were also performed.
Twelve studies including 991 patients met the criteria. The mean NOS score was 7.42 ± 1.19. Patients with high PD-L1 expression was associated with poorer PFS (HR = 1.90; 95% CI = 1.16-3.10; P = 0.011), while there was no association between PD-L1 expression and OS (HR = 1.19; 95% CI = 0.99-1.43; P = 0.070). Subgroup analysis prompted IHC scoring systems, IHC antibodies, and sample size have important effects on heterogeneity. The pooled results were robust according to the sensitivity analysis.
The result of this meta-analysis suggested that PD-L1 expression might be a predictive biomarker for EGFR-mutant non-small cell lung cancer treated with EGFR-TKIs.
基金：
National Natural Science
Foundation of China (NSFC 81602025), and the 1.3.5 Project for Disciplines of
Excellence (ZYJC18009), West China Hospital, Sichuan University. to Dr. Mei.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|3 区医学
小类|3 区外科4 区肿瘤学
最新[2023]版：
大类|3 区医学
小类|3 区肿瘤学3 区外科
第一作者：
第一作者机构：[1]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.[2]Chest Oncology Institute, West China Hospital, Sichuan University, Chengdu, China.[3]Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.[2]Chest Oncology Institute, West China Hospital, Sichuan University, Chengdu, China.[3]Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, China.
推荐引用方式(GB/T 7714)：
Peng Zhiyu,Lin Huahang,Zhou Ke,et al.Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis.[J].World journal of surgical oncology.2021,19(1):145.doi:10.1186/s12957-021-02254-x.
APA：
Peng Zhiyu,Lin Huahang,Zhou Ke,Deng Senyi&Mei Jiandong.(2021).Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis..World journal of surgical oncology,19,(1)
MLA：
Peng Zhiyu,et al."Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis.".World journal of surgical oncology 19..1(2021):145
